The China Stroke Primary Prevention Trial (CSPPT) is a large RCT (20,702 patients) that enrolled adults with hypertension without a history of stroke or myocardial infarction with determination of MTHFR genotype and baseline folate level. Here, MTHFR is linked to stroke disorder.